Control of exogenous agent characteristics in microbubble-mediated ultrasound procedures
Various approaches for microbubble-enhanced ultrasound treatment of target tissue include retrieving a treatment plan stored in memory; causing administration of an exogenous agent in accordance with the treatment plan; causing, in accordance with the treatment plan, an ultrasound transducer to transmit ultrasound waves to the target tissue and generate a focus therein in the presence of administered exogenous agent; receiving, from a monitoring system, a measured parameter value indicating a treatment condition in response to administration of the exogenous agent and transmission of the ultrasound waves during treatment; and adjusting the treatment plan based at least in part on the measured parameter value.
1. A system for microbubble-enhanced focused ultrasound treatment of target tissue, the system comprising:
an ultrasound transducer comprising a phased array of independently controllable transducer elements;
an administration device for administering an exogenous agent;
a monitoring system for measuring at least one parameter value associated with at least one of the ultrasound transducer, the exogenous agent, the target tissue, or non-target tissue;
computer memory storing a treatment plan specifying a disruption rate profile of the target tissue; and
at least one controller configured to:
(a) cause administration of the exogenous agent;
(b) drive at least some of the transducer elements at different phases to treat the target tissue by steering acoustic energy beams to the target tissue and generating a focus therein in the presence of administered exogenous agent;
(c) receive, from the monitoring system, the measured at least one parameter value indicating a treatment condition in response to administration of the exogenous agent and transmission of the ultrasound waves during treatment; and
(d) adjust a characteristic of the exogenous agent based at least in part on the measured at least one parameter value and the disruption rate profile.
2. The system of claim 1 , wherein the monitoring system comprises a biosensor, and the measured at least one parameter value comprises a physiological parameter value.
3. The system of claim 2 , wherein the physiological parameter value comprises at least one of a blood pressure, a blood circulation rate, a blood perfusion rate, a blood oxygen level or a heart rate.
4. The system of claim 2 , wherein the treatment plan specifies the characteristic of the exogenous agent, and the at least one controller is further configured to adjust the characteristic of the exogenous agent based at least in part on the measured physiological parameter value.
5. The system of claim 4 , wherein the characteristic of the exogenous agent comprises at least one of a type, a dose, a concentration profile, a temperature, or an administration profile of the exogenous agent.
6. The system of claim 5 , wherein the administration profile comprises at least one of an administration rate, an administration timing or an administration pressure of the exogenous agent.
7. The system of claim 4 , wherein the treatment plan specifies the disruption rate profile of the target tissue.
8. The system of claim 7 , wherein the treatment plan specifies an acoustic power profile associated with the ultrasound transducer, the at least one controller being further configured to adjust the acoustic power profile based at least in part on the adjusted characteristic of the exogenous agent.
9. The system of claim 1 , wherein the administration device is further configured to administer the exogenous agent, and the treatment plan specifies a characteristic of the microbubbles.
10. The system of claim 9 , wherein the microbubble characteristic comprises at least one of a diameter, a size distribution, a shell composition, a gas composition and/or a liquid core composition.
11. The system of claim 1 , wherein the monitoring system comprises an imager, and the measured at least one parameter value comprises a tissue characteristic of at least one of the target tissue or the non-target tissue.
12. The system of claim 11 , wherein the tissue characteristic comprises at least one of a temperature, a structure, a size, a shape or a location of the target tissue.
13. The system of claim 11 , wherein the treatment plan specifies a characteristic of the exogenous agent, and the at least one controller is further configured to adjust the characteristic of the exogenous agent based at least in part on the measured tissue characteristic of at least one of the target tissue or the non-target tissue.
14. The system of claim 1 , wherein the monitoring system comprises an acoustic-signal detector, and the measured at least one parameter value comprises at least one of ultrasound reflections or emissions from at least one of the target tissue or the non-target tissue.
15. The system of claim 14 , wherein the treatment plan specifies a characteristic of the exogenous agent, and the at least one controller is further configured to adjust the characteristic of the exogenous agent based at least in part on the measured ultrasound reflections and/or emissions.
16. The system of claim 15 , wherein the treatment plan specifies an acoustic power profile associated with the ultrasound transducer, and the at least one controller is further configured to adjust the acoustic power profile based at least in part on the adjusted characteristic of the exogenous agent or the measured ultrasound reflections and/or emissions.
17. The system of claim 1 , further comprising a radiation device for transmitting a radiation dose to the target tissue.
18. The system of claim 1 , further comprising a second administration device for administering a therapeutic agent to the target tissue.
19. The system of claim 18 , wherein the therapeutic agent comprises at least one of Busulfan, Thiotepa, CCNU (lomustine), BCNU (carmustine), ACNU (nimustine), Temozolomide, Methotrexate, Topotecan, Cisplatin, Etoposide, Irinotecan/SN-38, Carboplatin, Doxorubicin, Vinblastine, Vincristine, Procarbazine, Paclitaxel, Fotemustine, Ifosfamide/4-Hydroxyifosfamide/aldoifosfamide, Bevacizumab, 5-Fluorouracil, Bleomycin, Hydroxyurea, Docetaxel, or Cytarabine (cytosine arabinoside, ara-C)/ara-U.
20. The system of claim 18 , wherein the treatment plan specifies a characteristic of the therapeutic agent, and the at least one controller is configured to adjust the characteristic of the therapeutic agent based at least in part on the measured at least one parameter value.
21. The system of claim 20 , wherein the characteristic of the therapeutic agent comprises at least one of a type, a dose, a concentration profile, a temperature, an administration rate, an administration timing or an administration pressure of the therapeutic agent.
22. The system of claim 1 , wherein the ultrasound transducer, monitoring system, and administration device are controlled by three separate, intercommunicating controllers.
23. The system of claim 1 , wherein the ultrasound transducer and monitoring system are controlled by a first controller and the administration device is controlled by a second controller, the first and second controllers being in communication with each other, wherein the at least one controller comprises the first controller and the second controller.
24. The system of claim 1 , wherein the measured at least one parameter value is indicative of the treatment condition in response to an interaction between the administered exogenous agent and the transmitted ultrasound waves.
25. A system for microbubble-enhanced focused ultrasound treatment of target tissue, the system comprising:
an ultrasound transducer comprising a phased array of independently controllable transducer elements;
an administration device for administering at least one of an exogenous agent or a therapeutic agent;
a monitoring system for measuring at least one parameter value associated with at least one of the ultrasound transducer, the exogenous agent, the therapeutic agent, the target tissue, or non-target tissue;
computer memory storing a treatment plan that specifies a disruption rate profile of the target tissue, and a series of operations of the ultrasound transducer and the administration device so as to achieve a desired treatment effect on the target tissue; and
a controller configured to:
drive (i) at least some of the transducer elements of the ultrasound transducer at different phases to treat the target tissue by steering acoustic energy beams to the target tissue and generating a focus therein in the presence of administered exogenous agent or administered therapeutic agent and (ii) the administration device, based at least in part on the treatment plan; and
adjust a characteristic of the exogenous agent or the therapeutic agent based at least in part on the measured at least one parameter value and the disruption rate profile.